Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azithromycin Pre-treatment to Reduce Immunogenicity to Anti-TNF Agents in Crohn's Disease
NCT05599347Phase 2Recruiting
- Sponsor
- Rambam Health Care Campus
- Start
- Apr 2023
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azithromycin in Crohn's disease, sponsored by Rambam Health Care Campus. Started Apr 2023; status: recruiting.
02
Drugs
azithromycin
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT05599347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05599347.